



Investment objective

The fund seeks long-term growth of capital.

Portfolio management

Justin Livengood, Henry Wu

Fund facts

Nasdaq	A: GGHCX C: GTHCX
	Investor: GTHIX
	Y: GGHYX R6: GGHSX
Total Net Assets	\$1,649,741,200
Total Number of Holdings	92
Annual Turnover (as of 10/31/20)	17%
Distribution Frequency	Annually

Top 10 holdings (% of total net assets)

UnitedHealth	6.24
Danaher	4.15
Thermo Fisher Scientific	3.93
Eli Lilly	3.70
Intuitive Surgical	3.59
IDEXX Laboratories	3.41
AstraZeneca	3.16
HCA Healthcare	2.96
Abbott Laboratories	2.59
Agilent Technologies	2.45

Holdings are subject to change and are not buy/sell recommendations.

Expense ratios

	% net	% total
Class A Shares	1.07	1.07
Class C Shares	1.82	1.82
Investor Class Shares	1.07	1.07
Class Y Shares	0.82	0.82

Per the current prospectus

Statistics

Fund vs. Index	3 years	5 years
Alpha (%)	-0.89	-2.64
Beta	1.05	1.03
Up Capture (%)	100.81	95.86
Down Capture (%)	103.49	108.65

	fund	index
3-Year Standard Deviation	18.20	16.28


Source: StyleADVISOR; based on Class A shares and fund's style-specific index

A sector-oriented strategy that seeks to invest in equity securities of health care companies.

Performance of a \$10,000 investment

Class A shares at NAV (Sept. 30, 2011 - Sept. 30, 2021)

■ Invesco Health Care Fund - \$36,945



Investment results

Average annual total returns (%) as of Sept. 30, 2021

Period	Class A Shares		Class C Shares		Investor Class Shares		Style-Specific Index	S&P Composite 1500 Health Care Index
	Max Load 5.50% NAV	NAV	Max CDSC 1.00% NAV	NAV	NAV	NAV		
Inception	10.77	10.97	9.17	9.17	9.44	11.75	-	
10 Years	13.32	13.96	13.28	13.28	13.96	14.25	17.38	
5 Years	10.50	11.76	10.92	10.92	11.76	12.04	14.51	
3 Years	9.53	11.62	10.78	10.78	11.62	11.90	12.28	
1 Year	11.29	17.77	15.90	16.90	17.77	18.08	23.18	
Quarter	-4.78	0.76	-0.42	0.58	0.76	0.85	1.16	

Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Visit [invesco.com/performance](https://www.invesco.com/performance) for the most recent month-end performance. Performance figures reflect reinvested distributions and changes in net asset value (NAV). Investment return and principal value will vary, and you may have a gain or a loss when you sell shares. No contingent deferred sales charge (CDSC) will be imposed on redemptions of Class C shares following one year from the date shares were purchased. Performance shown at NAV does not include applicable CDSC or front-end sales charges, which would have reduced the performance. The Investor Class shares have no sales charge; therefore, performance is at NAV. Class Y shares have no sales charge; therefore, performance is at NAV. Returns less than one year are cumulative; all others are annualized. Fund performance reflects any applicable fee waivers and/or expense reimbursements. Had the adviser not waived fees and/or reimbursed expenses currently or in the past, returns would have been lower. See current prospectus for more information. Index returns do not reflect any fees, expenses, or sales charges.

Index source: FactSet Research Systems Inc.

Calendar year total returns (%)

Class A shares at NAV

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	YTD
	4.14	20.77	42.54	20.36	2.98	-11.71	15.46	0.46	32.00	14.45	5.75

■ On April 30, 2018, Invesco Global Health Care Fund was renamed Invesco Health Care Fund. Please see prospectus for more information.

Class Y shares and Investor Class shares are available only to certain investors. See the prospectus for more information. The fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

The S&P Composite 1500[®] Health Care Index consists of those companies included in the S&P Composite 1500 that are classified as members of the GICS[®] Health Care sector. An investment cannot be made directly in an index.

Alpha (cash adjusted) is a measure of performance on a risk-adjusted basis. **Beta** (cash adjusted) is a measure of relative risk and the slope of regression. The **up and down capture** measures how well a manager was able to replicate or improve on periods of positive benchmark returns and how severely the manager was affected by periods of negative benchmark returns.

Standard deviation measures a fund's range of total returns and identifies the spread of a fund's short-term fluctuations.

Not a deposit; Not FDIC insured; Not guaranteed by the bank; May lose value; Not insured by any federal agency


Top countries	(% of total net assets)
United States	89.92
United Kingdom	3.16
Switzerland	2.92
Denmark	1.82
Netherlands	0.63
China	0.17

Holdings are subject to change and are not buy/sell recommendations.

Asset mix (%)	
Dom Common Stock	89.92
Intl Common Stock	8.70
Cash	1.04
Other	0.34

A negative in Cash or Other, as of the date shown, is normally due to fund activity that has accrued or is pending settlement.

Equity sector breakdown (% of total net assets)



Health Care	98.71
Consumer Discretionary	0.00
Consumer Staples	0.00
Energy	0.00
Financials	0.00
Industrials	0.00
Information Technology	0.00
Materials	0.00
Real Estate	0.00
Communication Services	0.00
Utilities	0.00

Geographic diversification	(% of total net assets)
Region	
Europe	8.56
Asia	0.17
Latin America	0.00
Africa/Middle East	0.00
North America	89.98
Market	
Developed Market Exposure	98.54
Emerging Markets Exposure	0.17
Other Markets Exposure	0.00

Top industries	(% of total net assets)
Health Care Equipment	26.05
Life Sciences Tools & Services	17.87
Biotechnology	17.39
Pharmaceuticals	14.31
Managed Health Care	7.99
Health Care Supplies	5.19
Health Care Facilities	4.29
Health Care Technology	3.60
Health Care Services	1.93

Holdings are subject to change and are not buy/sell recommendations.

About risk

In general, stock and other equity securities values fluctuate, sometimes widely, in response to activities specific to the company as well as general market, economic and political conditions.

Convertible securities may be affected by market interest rates, the risk of issuer default, the value of the underlying stock or the issuer's right to buy back the convertible securities.

Derivatives may be more volatile and less liquid than traditional investments and are subject to market, interest rate, credit, leverage, counterparty and management risks. An investment in a derivative could lose more than the cash amount invested.

The risks of investing in securities of foreign issuers, including emerging markets, can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

The performance of an investment concentrated in issuers of a certain region or country is expected to be closely tied to conditions within that region and to be more volatile than more geographically diversified funds.

The health care industry is subject to risks relating to government regulation, obsolescence caused by scientific advances and technological innovations.

Preferred securities may include provisions that permit the issuer to defer or omit distributions for a certain period of time, and reporting the distribution for tax purposes may be required, even though the income may not have been received. Further, preferred securities may lose substantial value due to the omission or deferment of dividend payments.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

The fund is subject to certain other risks. Please see the current prospectus for more information regarding the risks associated with an investment in the fund.

Before investing, investors should carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund(s), investors should ask their advisors for a prospectus/summary prospectus or visit invesco.com/fundprospectus.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Note: Not all products available at all firms. Financial professionals, please contact your home office.

All data provided by Invesco unless otherwise noted.